Which sub sectors of European HealthTech and MedTech are most likely to see consolidation in 2026?
- Nelson Advisors
- Dec 28, 2025
- 18 min read
European HealthTech and MedTech Consolidation Outlook 2026: The Great Rationalisation and the Industrialisation of Care
The European healthcare technology and services landscape is entering 2026 at a profound inflection point. After a period of post-pandemic recalibration in 2024 and a tentative recovery in 2025, the market is poised for a robust, albeit structurally transformed, resurgence in mergers and acquisitions (M&A). The defining theme for 2026 is "Industrialisation."
This concept signifies a departure from the fragmented, venture subsidised experimentation that characterised the 2019–2022 era, moving instead toward scalable, profit generating platforms that leverage operational leverage, regulatory fortitude and vertical integration to dominate their respective sub-sectors.
The consolidation wave of 2026 will not be a rising tide that lifts all boats. Instead, it will be defined by a stark bifurcation in asset desirability and deal rationale. On one side of the ledger, "Analog" healthcare services, encompassing veterinary, dental, ophthalmology and fertility clinics will witness continued intensified "buy-and-build" activity. This is driven principally by private equity (PE) sponsors seeking to arbitrage highly fragmented markets, particularly in Southern and Eastern Europe, where entry multiples remain attractive relative to the saturated markets of the UK and the Nordics. On the other side, "Digital" and high-technology segments, including AI-enabled radiology, digital pathology and tech-enabled home care, will experience strategic consolidation.
Here, hardware incumbents and large-cap technology firms will acquire software innovators not merely for growth, but to secure data sovereignty and "compliance moats" in the face of an increasingly rigorous EU regulatory architecture.
Three primary catalysts will underpin the deal flow in 2026, creating a unique pressure cooker for M&A activity:
First, Regulatory Darwinism will force a clearing event. The full implementation of the EU Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) has created a capital-intensive barrier to entry that is largely untenable for stand-alone Small and Medium-sized Enterprises (SMEs). The costs associated with Notified Body certification and clinical data generation act as a guillotine for undercapitalized firms, driving them into the arms of larger strategics who possess the necessary regulatory infrastructure. Simultaneously, the new EU AI Act and Digital Omnibus introduce complex compliance requirements for high-risk AI systems, effectively barring new entrants who lack the resources for robust data governance and post-market surveillance.
Second, the Private Equity Liquidity Cycle is reaching a critical maturity. With approximately $2.5 Trillion in global dry powder and a significant backlog of assets from the 2019–2021 vintage requiring exit, PE firms are under immense pressure to return capital to Limited Partners (LPs). However, with the IPO market remaining selective and focused only on assets with proven profitability and scale, sponsors will increasingly utilise continuation funds and secondary buyouts to drive consolidation. This allows them to hold high performing assets for longer, financing further add-on acquisitions to build pan-European champions before an eventual exit.
Third, the Structural Shift to Outpatient and Home Settings is reallocating capital. Health systems across Europe, burdened by aging populations and workforce shortages, are aggressively pushing care out of high cost hospital settings. This is fuelling a massive capital rotation toward technologies and services that facilitate "hospital-at-home" models, remote monitoring and decentralised diagnostics.
M&A in 2026 will heavily favour assets that enable this transition, such as tech-enabled home care providers and outpatient surgery centres, which offer an immediate release valve for strained public health budgets.
This report provides an analysis of these dynamics, dissecting the market into key verticals of consolidation, financial mechanisms, and regional hotspots to offer a comprehensive outlook for 2026.
The Regulatory and Macro-Financial Architecture
The regulatory environment in Europe has shifted from being a mere compliance hurdle to becoming the single most significant driver of structural consolidation. The transition periods for the MDR and IVDR have fundamentally altered the unit economics of MedTech innovation.
The MDR/IVDR Squeeze
For decades, Europe was the "First Launch" market of choice for medical devices due to a perceived faster pathway to CE marking compared to FDA approval in the US. This dynamic has inverted. The stringent clinical evidence requirements, post-market surveillance obligations, and the bottleneck of Notified Body capacity under MDR/IVDR have dramatically increased the time and cost to market. By 2026, the extended transition periods for legacy devices will be nearing their end for high-risk classes, forcing companies to make hard decisions about portfolio rationalisation.
Many SMEs, particularly in the In Vitro Diagnostics (IVD) space, are facing an existential crisis. The IVDR requires approximately 80% of IVDs to undergo Notified Body assessment, compared to less than 20% under the old directive. The cost of remediating technical files and conducting performance studies is often prohibitive for smaller firms with limited product portfolios. Consequently, 2026 will see a wave of "compliance-driven M&A," where large strategics acquire the intellectual property and customer bases of SMEs that cannot afford the regulatory transition. These acquirers, companies like Roche, Siemens Healthineers and Abbott, possess the scaled regulatory affairs departments and Notified Body relationships to navigate the landscape efficiently.
The AI Act and Digital Omnibus:
2026 also marks a pivotal year for digital health regulation with the implementation of the EU AI Act and the proposed Digital Omnibus. The AI Act categorises many medical AI tools (eg. radiology triage software, clinical decision support) as "high-risk," mandating rigorous data governance, human oversight and cybersecurity standards.
The Digital Omnibus package, introduced to streamline the interplay between the AI Act, MDR and GDPR, includes the "Data Unlock" concept. This aims to facilitate the secondary use of health data for AI training, a critical enabler for the next generation of algorithms. However, navigating the "Digital Fitness Check" and the overlapping requirements of the AI Act and MDR creates a complex legal matrix.
This regulatory density creates a "compliance moat." Startups that have already achieved compliance or possess large, GDPR-compliant datasets become highly valuable targets. Conversely, early-stage AI companies that have "moved fast and broken things" without robust regulatory foundations will find themselves uninvestable or distressed targets. Acquirers in 2026 will conduct exhaustive regulatory due diligence, viewing a target's regulatory profile as a core financial asset or liability.
The Private Equity "Dry Powder" and the Liquidity Imperative
The financial backdrop for 2026 is defined by a massive overhang of unallocated capital alongside a pressing need for liquidity events.
The Dry Powder Overhang
Global private equity funds are sitting on nearly $2.5 Trillion in dry powder. This capital must be deployed, but the investment criteria have shifted radically since the zero interest rate era. The "growth-at-all-costs" thesis has been replaced by a focus on unit economics, EBITDA expansion and cash flow predictability.
In 2026, this capital will be directed toward "platform" creations. PE firms will look to deploy large equity checks into mature, cash-generative businesses, such as CDMOs, CROs and multi-site healthcare providers that can serve as consolidators. The goal is to execute "buy-and-build" strategies that blend organic growth with multiple arbitrage, acquiring smaller competitors at lower valuations (eg. 6x-8x EBITDA) and integrating them into a larger platform valued at a premium (eg. 12x-15x EBITDA).
The Exit Dilemma and Continuation Funds
A significant challenge for the PE industry in 2026 is the backlog of assets acquired during the 2018–2021 vintage. Many of these investments are reaching the end of their traditional holding periods. However, with the IPO market expected to remain selective and accessible primarily to "mega-cap" listings or highly profitable tech-enabled firms, exits via public markets will be limited.
Consequently, we anticipate a surge in Continuation Funds. Sponsors will move high-performing assets from older funds into new vehicles, allowing them to return capital to original LPs while retaining ownership of the asset to drive further growth. This mechanism effectively extends the investment horizon, enabling the PE firm to finance further bolt-on acquisitions and complete the consolidation play before eventually exiting to a strategic buyer or attempting an IPO in a more favourable window. This trend reinforces the "industrialisation" theme, as assets are held longer and managed more intensively to drive operational efficiencies.
The 2026 Investment Matrix - Capital Sources and Strategic Motivations
Capital Source | Primary Strategic Motivation | Target Asset Profile | Key Geographic Focus |
Private Equity (Large Cap) | Platform Creation & Multiple Arbitrage | Revenue Cycle Management (RCM), CDMOs, Pan-European Clinic Chains | UK, Germany, Benelux |
Strategic Acquirers (MedTech) | Vertical Integration & Data Sovereignty | AI Radiology, Surgical Robotics, Connected Care Platforms | France, Israel (Innovation Hubs), DACH |
Venture Capital (Late Stage) | Portfolio Consolidation & Survival | Digital Therapeutics (DiGA), Hybrid Telemedicine Models | Germany, Nordics, UK |
Sovereign Wealth / Infrastructure Funds | Long-term Yield & Inflation Hedge | Real Estate-heavy Care Homes, Private Hospital Groups | UK, Southern Europe |
Healthcare Services: The Engine of Volume Consolidation
The healthcare services sector remains the most active arena for volume-based consolidation in Europe. The fragmentation of service providers, ranging from single-dentist practices to small veterinary clinics, offers a classic playbook for private equity: acquire a platform asset, standardise back-office operations (billing, procurement, IT) and aggressively roll up smaller competitors to achieve economies of scale.
Dental Services: From General Practice to Specialised Ecosystems
The European dental market is undergoing a profound transformation. While general dentistry remains the foundational revenue stream, the consolidation wave in 2026 is distinct in its focus on specialty clusters, specifically implantology, orthodontics, and aesthetics as well as its geographic migration.
Technological Imperatives Driving Sales
The practice of dentistry is becoming increasingly capital-intensive. The standard of care now involves digital workflows including intraoral scanners, Cone Beam CT (CBCT) imaging, and chairside 3D printing or milling units. The cost of equipping a modern digital practice can exceed hundreds of thousands of euros. Independent practitioners, facing rising inflation and wage pressures, often cannot afford this CAPEX. Large Dental Service Organizations (DSOs) leverage their scale to procure this technology at a discount and amortise the cost across a network of clinics. This technological gap is a primary driver accelerating the sale of independent practices to groups like PortmanDentex, Colosseum Dental Group and Riverdale Healthcare.
Geographic Bifurcation
Consolidation maturity varies significantly across Europe. In markets like the Netherlands and the UK, consolidation is advanced, with significant portions of the market already integrated into corporate groups. Here, the focus in 2026 will be on "secondary buyouts", larger groups merging to create super-platforms and operational optimisation.
However, the true frontier for volume consolidation in 2026 lies in Eastern and Southern Europe. Markets like Bulgaria, Romania and Spain are seeing increased interest from pan-European investors. In these regions, the dental sector is highly fragmented, but the emergence of a growing middle class is driving demand for private, out-of-pocket cosmetic dentistry. Investors are attracted by the lower entry multiples (often buying clinics at 4x-6x EBITDA compared to 8x-10x in Western Europe) and the opportunity to introduce professional management to rapidly growing practices.
Strategic Shift to Specialty
Investors are increasingly wary of exposure to government reimbursed general dentistry due to constant pricing pressures and budget caps. Consequently, M&A activity in 2026 will prioritise practices with high "private pay" ratios. Clinics specialised in high-margin procedures such as clear aligners (orthodontics) and implants are particularly prized. This aligns with the broader trend of consumerisation in healthcare, where patients act as consumers paying for perceived quality and aesthetic improvements, insulating the business from public payer austerity.
Veterinary Services: The Corporatisation Clash and the "Locum" Crisis
The veterinary sector represents a mature consolidation play in the UK and Nordics but retains significant runway in Continental Europe. However, 2026 brings substantial headwinds in the form of regulatory scrutiny and workforce dynamics.
The Regulatory Backlash
The aggressive consolidation of veterinary practices has caught the eye of competition authorities. In the UK, the Competition and Markets Authority (CMA) has launched investigations into the pricing power and market dominance of large veterinary groups. This regulatory spotlight is expected to slow the pace of mega-mergers in the UK and potentially force divestitures of clinics in concentrated local markets.
This "CMA Effect" is pushing capital toward the Continent. Investors are redirecting funds to France, Germany and Italy, where corporate ownership levels are significantly lower (15-20%) compared to the UK (approx. 60%). In 2026, we expect intense M&A activity in Southern Europe as PE-backed groups race to build scale before similar regulatory scrutiny emerges in these jurisdictions.
The Workforce Crisis as a Deal Driver
A critical operational challenge driving consolidation is the acute global shortage of veterinarians. The rise of the "locum" workforce (temporary staff) is driving up wage bills and squeezing margins for independent practices. Independent clinic owners, exhausted by the administrative burden of recruitment and unable to match the flexibility or salaries offered by agencies, are increasingly motivated sellers.
Corporates that can offer centralized recruiting, visa sponsorship for international vets and better technology (eg. AI triage, tele-consultation) to reduce burnout have a distinct advantage. In 2026, acquiring a clinic is often less about acquiring the customer list and more about acquiring the clinical staff. Large groups like IVC Evidensia and AniCura are shifting their value proposition to potential sellers, emphasising their ability to provide stability, career progression and relief from administrative drudgery.
Ophthalmology and Fertility: The High-Margin Enclaves
Beyond dental and vet, ophthalmology and fertility (IVF) services are emerging as prime targets for consolidation in 2026. Both sectors share attractive characteristics: high barriers to entry (specialised equipment and licensing), strong secular tailwinds (aging population for ophthalmology, delayed parenthood for IVF) and a significant component of private-pay revenue.
Ophthalmology
The shift of cataract surgery and other ophthalmic procedures from inpatient to outpatient settings is a major trend. High-volume, efficient outpatient clinics can deliver these procedures at a lower cost than hospitals. Companies like EssilorLuxottica are vertically integrating by acquiring clinic chains (eg. Optegra) to capture the value of the surgery and the subsequent prescription lenses. In 2026, we expect further consolidation of independent eye clinics into regional platforms, particularly in France and Germany, driven by the need to invest in expensive femtosecond laser technology.
Fertility (IVF)
The fertility sector is forecasted to grow steadily, driven by declining fertility rates and the increasing availability of treatment. The market remains fragmented, with many clinics operated by founder-physicians. PE firms are attracted to the "consumer" nature of IVF, where patients are highly motivated and often pay out-of-pocket. Consolidation allows for the centralisation of expensive embryology labs and marketing functions. In 2026, we anticipate cross-border mergers creating pan-European fertility groups that can offer "fertility tourism" options, leveraging lower costs in countries like Spain or the Czech Republic for patients from higher-cost jurisdictions.
Radiology and Imaging Centres: Capital Intensity Meets AI
Radiology presents a unique intersection of service delivery and high technology. Unlike other service sectors, radiology is extremely capital-intensive, requiring regular investment in expensive MRI, CT and PET-CT scanners.
The Capital-AI Nexus
In 2026, consolidation in radiology is driven by the dual need to amortise the cost of hardware upgrades and to integrate Artificial Intelligence. Independent imaging centres struggle to afford the latest state-of-the-art scanners or the IT infrastructure required to deploy AI diagnostic tools effectively. Large groups like Affidea, Unilabs, and Alliance Medical can leverage their scale to negotiate better procurement deals with OEMs and implement centralised AI platforms.
Teleradiology and the "Hub-and-Spoke" Model
The shortage of radiologists is as acute as that of veterinarians. Consolidated groups are increasingly adopting a "hub-and-spoke" model, where images acquired at local centres are read remotely by sub-specialists in a central hub (or even in a different country within the network). This teleradiology capability allows groups to balance workloads, reduce turnaround times, and offer 24/7 coverage, a service level that independent centres cannot match.
Research indicates that PE-backed and hospital-based radiology groups command significantly higher prices for their services than independent groups. This pricing power reinforces the investment thesis for PE. In 2026, we expect to see the formation of cross-border radiology platforms (eg. expanding from France/Germany into Benelux and Italy) to leverage these teleradiology networks and regulatory arbitrage.
MedTech Industrial Strategies: Hardware Meets Software
The traditional MedTech sector, encompassing imaging hardware, surgical robotics, and devices is pivoting aggressively toward data and software. In 2026, the distinction between "MedTech" (hardware) and "HealthTech" (software) will blur further as hardware manufacturers acquire software capabilities to differentiate their commoditised equipment and lock in customers.
Imaging and Diagnostics: The Software-Defined Scanner
Major Original Equipment Manufacturers (OEMs) like Siemens Healthineers, GE HealthCare, and Philipsare engaging in a race to own the "Operating System of Radiology." While the hardware market is mature and growing at mid-single digits, the segments for "Digital" and "AI" solutions are growing at double-digit rates.
Deconsolidation and Strategic Agility
A significant catalyst in 2026 is the planned deconsolidation of Siemens Healthineers by its parent company Siemens. This move is designed to give Healthineers greater strategic agility and a dedicated currency (its own stock) for M&A. We predict Siemens Healthineers will use this independence to aggressively acquire AI startups in the imaging space.
The target profile for these acquisitions will be companies with FDA-cleared/CE-marked AI algorithms for specific high-burden pathologies (eg. stroke, lung nodules, breast cancer, prostate cancer). Startups like Aidoc, DeepHealth, Gleamer or Qure.ai are prime targets.
The Strategic Logic: Hospitals are overwhelmed by the proliferation of point-solution AI apps. They do not want to sign 50 different contracts with 50 startups. They prefer a "single pane of glass", a unified platform integrated into their PACS (Picture Archiving and Communication System). OEMs are positioning themselves to bundle these best-in-class AI apps directly into their equipment or PACS offerings, effectively becoming the "App Store" for radiology. Acquiring the software vendors allows the OEMs to capture the recurring SaaS revenue and deepen their entrenchment in the hospital workflow.
Digital Pathology: The Year of Industrialisation
Pathology is following the digitisation trajectory of radiology but is approximately 5-10 years behind. 2025–2026 is widely viewed as the "industrialisation" phase for digital pathology.
From Point Solutions to Foundation Models
The market is shifting from "single-disease" AI models (eg. an algorithm that just detects prostate cancer) to "multimodal foundation models" that can analyse tissue samples across various diseases and integrate genomics and clinical data.
Consolidation Activity: We expect hardware vendors (scanner manufacturers like Leica Biosystems, Hamamatsu, Roche) to forge deep equity partnerships with or acquire AI pathology software firms (such as Indica Labs, Paige, Ibex, Proscia).
The rationale is to sell a complete "scan-and-analyse" solution. Community hospitals and smaller labs often lack the IT resources to integrate disparate scanners, viewers, and AI tools. A vertically integrated solution that "just works" out of the box is essential to drive adoption beyond top-tier academic centres.
Furthermore, with the FDA and Notified Bodies increasingly approving AI for primary diagnosis, the value of these software assets is validated, triggering M&A interest.
CDMOs: Supply Chain Sovereignty and Complexity
The Contract Development and Manufacturing Organisation (CDMO) sector is operating in a "protectionist" era. Geopolitical tensions, exemplified by the US Biosecure Act, are driving a wedge between Western pharma companies and Chinese CDMOs. This is creating a massive opportunity for European CDMOs.
Friend-Shoring and Specialisation
In 2026, European CDMOs will be prime acquisition targets for US Private Equity and Strategic buyers looking to "friend-shore" their supply chains and secure capacity outside of China.
However, generalist CDMOs are less attractive than specialists. We expect consolidation to cluster around complex modalities, specifically viral vectors (for cell & gene therapy), Antibody-Drug Conjugates (ADCs) and sterile injectables (driven by the insatiable demand for GLP-1 agonists).
The "one-stop-shop" model is evolving into a "specialised network" model. Acquirers are rolling up niche CDMOs with specific capabilities (eg. a leader in lipid nanoparticles + a leader in sterile fill-finish) to offer end-to-end services for these complex therapies. This strategy mitigates supply chain risk for pharma clients and allows the CDMO to capture higher margins associated with difficult-to-manufacture biologics.
Digital Health and HealthTech: From Fragmentation to Platformisation
The digital health sector in 2026 is predicted to undergo a "clearing event." The market is bifurcating into "Industrialised Platforms" that have achieved scale and integration and "Distressed Assets" that remain as point solutions. Hospitals and payers are fatigued by the fragmentation of digital tools and are demanding unified platforms that integrate seamlessly into Electronic Health Records (EHRs).
Home Care Technology: The Logistics of the "Hospital at Home"
Home care is transitioning from a low-tech, labour intensive sector to a high-tech logistics operation. With hospital capacity strained, the "hospital-at-home" model is a policy priority across Europe (eg. NHS Virtual Wards). Companies like Cera and Birdie are at the forefront of this transformation.
The Tech-Enabled Roll-Up
Cera's acquisition strategy illustrates the 2026 playbook: acquire traditional, volume-heavy home care agencies and overlay a proprietary technology stack (AI scheduling, remote monitoring, predictive analytics) to improve margins and outcomes. Cera's acquisition of GenieConnect (robotics) and Care at Home Services (traditional provider) demonstrates this hybrid approach.
The value proposition is clear: the acquirer brings the "operating system" that makes the traditional agency profitable. By optimising routes, predicting adverse events (falls, UTIs) to prevent hospitalisations and automating compliance, the tech-enabled platform can generate higher EBITDA margins than the analogue agency it acquires. In 2026, we expect this model to scale aggressively across the UK and Germany, with tech-enabled providers rolling up struggling local agencies.
SaaS Platforms
On the software side, companies like Birdie provide the SaaS infrastructure for independent agencies. We may see consolidation among these SaaS providers or acquisitions by larger HCIT players (eg. Access Group) seeking to dominate the social care vertical.
Telemedicine: The Hybrid Pivot and Vertical Integration
Pure play telemedicine has faced a reckoning as valuations crashed from their pandemic highs. The future is hybrid (digi-physical). Players like Doctolib (France), Kry/Livi (Sweden/UK/France) and Doctor Anywhere are consolidating the "digital front door" to healthcare.
Vertical Integration Strategies
Successful platforms are moving beyond just connecting patients to doctors via video. They are acquiring physical clinics (primary care) to capture the full patient journey and the associated reimbursement. Kry’s expansion into physical units in Sweden and France serves as the blueprint. Owning the physical touchpoint allows the platform to manage chronic conditions, perform diagnostics, and capture downstream revenue that a purely virtual model misses.
Antitrust Risks
The sector faces significant regulatory scrutiny. The French Competition Authority’s fine on Doctolib for its acquisition of MonDocteur signals that competition watchdogs are monitoring "killer acquisitions" in the digital health space, even those below traditional notification thresholds. This creates a headwind for mega-mergers between direct competitors. Consequently, we expect large platforms to pursue "vertical" M&A (buying clinics, software tools for doctors) rather than "horizontal" M&A (buying rival booking platforms) to avoid antitrust challenges.
Digital Therapeutics (DiGA): The Shakeout
Germany’s DiGA (Digital Health Applications) system remains the gold standard for digital reimbursement in Europe. However, with nearly 60 apps reimbursed and the market maturing, a shakeout is imminent.
The "Platform" Thesis
In 2026, standalone apps for single conditions (eg. an app solely for depression) will struggle to scale against multi-indication platforms. Payers and doctors prefer prescribing a single "mental health ecosystem" rather than navigating dozens of niche apps. We anticipate mergers between complementary DiGA companies, for example, a mental health app merging with a chronic pain management solution or a diabetes management tool, to create "comorbidity platforms".
Furthermore, the requirements for interoperability and evidence generation under the DiGA framework and the upcoming European Health Data Space (EHDS) favour larger players. Smaller startups unable to afford the clinical trials required for permanent listing will be acquired for their IP or user base by larger platforms or pharma companies seeking "beyond the pill" solutions.
Private Equity & Capital Markets Dynamics
The Rise of the Continuation Fund
Private Equity behaviour in 2026 will be dictated by the "vintage" problem. Funds that bought assets in the high-valuation era of 2020–2021 are under pressure to show returns, but selling these assets in the current market might crystallize a loss or a sub-par return.
Instead of forcing an exit, PE firms will increasingly utilise Continuation Funds. This mechanism allows the PE firm to sell the asset from its old fund to a new fund managed by the same firm. This provides liquidity to original Limited Partners (LPs) who want out, while giving the General Partner (GP) more time and fresh capital to execute the next phase of growth.
This trend reinforces consolidation. The "new" capital in the continuation fund is often earmarked for add-on acquisitions. Thus, a platform asset that might have been sold to a strategic buyer in 2021 is instead retained and empowered to go on a buying spree in 2026.
Deal Structures in a High-Rate Environment
Although interest rates have stabilised, the cost of debt remains higher than in the pre-2022 era. To bridge valuation gaps between sellers (who still remember 2021 prices) and buyers (focused on 2026 reality), deal structures in 2026 will be creative.
Earn-outs: A significant portion of deal value (20-30%) will be contingent on post-closing performance. This is particularly prevalent in AI and digital health deals, where revenue trajectories are steep but unproven.
Minority Recaps / Rollovers: Founders will be asked to "roll over" a significant portion of their equity (30-40%) into the new entity. This reduces the cash outlay for the PE buyer and aligns incentives for the next growth phase.
Vendor Financing: In some cases, sellers may offer financing to the buyer to get the deal done, essentially lending the buyer the money to buy the company.
Regional Heatmaps: Consolidation Hotspots
UK: The epicenter of "Regulatory Divergence." The CMA's scrutiny of vet pricing is a key theme. The NHS 10-Year Plan is driving investment into home care and digital tools to reduce waiting lists. M&A is active in social care and specialty clinics.
DACH (Germany, Austria, Switzerland): The "DiGA Laboratory." Germany is the hub for digital therapeutics consolidation. The hospital sector is also consolidating due to insolvency pressures on smaller municipal hospitals, creating opportunities for private hospital groups.
France: The "National Champion" market. Policy favours domestic consolidation to create strong French players (e.g., Doctolib, Essilor). The "PECAN" reimbursement scheme for digital health is stimulating the market. Antitrust enforcement is high.
Southern Europe (Spain, Italy): The "Growth Frontier." Fragmented markets in dental and vet services are attracting significant PE capital. These markets offer the best "buy-and-build" opportunities due to lower consolidation maturity.
Benelux: A mature, highly consolidated market serving as a testing ground for integrated care models. High deal activity in radiology and labs.
Conclusion: The Great Rationalisation
2026 will be defined as the year of Rationalisation in European HealthTech and MedTech. The market is moving away from hype and fragmentation toward a disciplined industrial logic.
For Services: It is a game of scale, operational efficiency and geographic arbitrage (moving South/East).
For Tech: It is a game of vertical integration, data sovereignty and navigating the "compliance moat."
Investors and corporates must navigate a complex matrix of regulatory deadlines (MDR/AI Act) and financial opportunities (PE dry powder). The winners in 2026 will not necessarily be the ones with the most disruptive technology, but those with the most robust operating platforms, capable of navigating the regulatory maze, integrating acquisitions effectively and delivering measurable EBITDA improvements in an increasingly cost-constrained healthcare environment. The industry is graduating from the "laboratory" phase to the "factory" phase, and consolidation is the primary mechanism of this maturation.
Nelson Advisors > MedTech and HealthTech M&A
Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk
Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital
We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb
Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk
#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech
Nelson Advisors LLP
Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT
Meet Us @ HealthTech events
October 2025
Healthcare Summit 2025, London, UK – Chairing the HealthTech M&A Panel
Healthcare Summit 2025, London, UK – Chairing the HealthTech Deal Structuring Panel
NHS Clinical Entrepreneur Conference, Belfast, Northern Ireland
Global Health Exhibition 2025, Riyadh, Saudi Arabia – Chairing the HealthTech M&A Panel
November 2025
HealthTech X Summit, London, UK – Chairing the “HealthTech predictions for 2026” Panel
MedTech Europe 2025, Valletta, Malta- Speaker on the "Startups, Corporates & Hospitals: How to Build Meaningful MedTech Partnerships" panel
MedTech Europe 2025, Valletta, Malta- Judge for the MedTech StartUp Pitch Awards
Leaders in Health Summit 2025
December 2025
HealthTech Forward 2025, Barcelona, Spain – Moderating the Health Data Under Attack” Panel
Healthcare Club, IESE Business School, Barcelona, Spain
HealthInvestor Power List Awards 2025, London, UK – Judging Panel
